Grâce à son organisation horizontale et à sa structure administrative simple, le Réseau de médecine régénérative de McGill peut saisir rapidement les occasions qui s’offrent à lui.

Une personne choisie par la Faculté de médecine et la vice-principale (recherche et innovation) en assure la direction pendant quatre ans. Ce directeur est épaulé par un coordonnateur, et son mandat est approuvé par le comité exécutif du Réseau MRM, composé de chercheurs de tous les départements.

De plus, le Réseau MRM compte sept comités voués à la réalisation des cinq engagements de sa stratégie globale.

 

Administration

Prof. Michel L. Tremblay

Directeur
        
En savoir plus

Prof. Michel L. Tremblay

Directeur

Dr. Michel L. Tremblay, Ph.D. is a James McGill Professor and former director of the Goodman Cancer Research Centre His laboratory works on characterizing the function and regulation of several members of the Protein Tyrosine Phosphatase (PTP) gene family using both biochemical and genetic approaches. Dr. Tremblay’s lab is also developing several new approaches towards PTP inhibition, as well as large siRNA gene family screens in order to uncover potential applications of these in various diseases (diabetes, obesity, spinal cord injury, neural degenerative diseases, intestinal bowel diseases and other inflammatory diseases), particularly in human cancers.

Dr. Marine Christin

Coordinatrice
        
En savoir plus

Dr. Marine Christin

Coordinatrice

Contact:

Courriel: mrm.coordinator@mcgill.ca

Tél: 514-398-7595

Comité Exécutif

Dr. Inés Colmegna

Division de Rhumatologie, IR-CUSM
        
En savoir plus

Dr. Inés Colmegna

Division de Rhumatologie, IR-CUSM

My lab research focuses on defining basic mechanisms involved in the disruption of immune tolerance in patients with rheumatoid arthritis (RA). We are specifically interested in understanding the role that adult stem cells have in initiating and perpetuating this disease. Ongoing studies aim to characterize the biology of human hematopoietic and mesenchymal stem cells in patients with recent onset and established RA, the cross talk between stem cells and other immune cells, and the impact that interventions targeting stem cells have on the restoration of immune function.

Dr. Colin Crist

Génétique Humaine, Institut Lady Davis
        
En savoir plus

Dr. Colin Crist

Génétique Humaine, Institut Lady Davis

Dr. Crist’s laboratory at the Lady Davis Institute for Medical Research investigates the molecular biology underlying skeletal muscle development and regeneration. Deepening our understanding of how muscle stem cells develop and function will be key to realizing regenerative medicine based approaches to treating muscle disorders.

Dr. Thomas Durcan

Neurologie et Neurochirurgie, Institut Neurologique de Montréal
        
En savoir plus

Dr. Thomas Durcan

Neurologie et Neurochirurgie, Institut Neurologique de Montréal

As an assistant professor at the Montreal Neurological Institute (MNI) and McGill University, my research focus is on applying patient-derived stem cells towards the development of phenotypic discovery assays and 3D mini-brain models for both neurodegenerative and neurodevelopmental disorders. As group leader of the iPSC platform at the Montreal Neurological Institute (MNI), I oversee a team of 30 research staff and students and growing, committed to applying novel stem cell technology, combined with CRISPR genome editing, mini-brain models and new microfluidic technologies towards elucidating the underlying causes of these complex disorders. Leading the SGC tissue platform, NeuroSGC; I oversee a team committed to assay development, in parallel with leading the establishment of NeuroCDRD, towards the automation of our open assays for small molecule screens. In addition, I am also part of antibody validation efforts between the MNI, Oxford and the Karolinska to generate CRISPR KO cell-lines for validating commercial antibodies against high-value ALS targets. Combined with new approaches in the group towards building multiomic profiles on the patient-derived IPSC cells within the group, the long-term strategy over the coming years is to identify new personalized precision therapies that can be applied towards building clinical trials on a dish.

Dr. Carl Ernst

Psychiatrie, Institut Douglas
        
En savoir plus

Dr. Carl Ernst

Psychiatrie, Institut Douglas

Carl Ernst, is currently a professor at McGill in the departments of Human Genetics, Neuroscience, and Psychology. The goal of his work is to study human behaviour and mood by identifying genes that may be involved in mental disorders. For this work, he produces cellular models based on the functions of specific genes, and screens at-risk populations for genetic mutations, deriving stem cells from their tissues. He then assesses how neurons derived from these subjects’ stem cells differ from neurons derived from healthy patients.

Dr. Alex Gregorieff

Pathologie, IR-CUSM
        
En savoir plus

Dr. Alex Gregorieff

Pathologie, IR-CUSM

One of the extraordinary abilities of all living creatures is their capacity to repair damaged tissues following injury. This regenerative property is in large part due to the existence of stem cells that are defined by their ability to replace themselves through division, as well as giving rise to specialized cell types through a process known as differentiation. Unfortunately, once stem cells acquire mutations that cause them to proliferate incessantly, they can also fuel cancer growth. My lab focuses on the stem cells in the epithelial lining of our intestinal tract. By constantly replenishing the gut epithelium, intestinal stem cells ensure proper nutrient uptake and barrier formation against environmental toxins and pathogens throughout life. My interests lie in understanding the signals that control gut stem cell behaviour and how these signals become misregulated in diseases such as inflammatory bowel disease and colon cancer.

Prof. Terry Hébert

Pharmacologie
        
En savoir plus

Prof. Terry Hébert

Pharmacologie

Terry Hébert’s research focus is on the ontogeny, formation and trafficking of GPCR-based signalling complexes with a view toward understanding the architecture, wiring and integration of individual GPCR signalling pathways both at the cell surface and in the nucleus. Our primary focus is in the context of cardiovascular disease. He has developed new methods for in cellulo measures of protein/protein interactions and is highly involved in the development of new multiplexed signalling assays for drug discovery. The lab is now poised to exploit patient-derived iSPC lines to develop personalized understanding of disease and its treatment.

Dr. Corinne Hoesli

Génie Chimique
        
En savoir plus

Dr. Corinne Hoesli

Génie Chimique

The Stem Cell Bioprocessing Laboratory works on engineering bioreactors for stem cell culture. We apply engineering approaches to design, optimize and scale up stem cell production systems. We are currently investigating the effects of various biomaterials and 3D culture on pluripotent stem cell differentiation into pancreatic cells as well as vascular endothelial cells. The main areas of applications of our research are diabetes cellular therapy and the development of vascular substitutes to treat cardiovascular disease.

Me Erika Kleiderman

Génétique Humaine, Centre de génomique et politiques
        
En savoir plus

Me Erika Kleiderman

Génétique Humaine, Centre de génomique et politiques

Erika Kleiderman is a lawyer and an Academic Associate at the Centre of Genomics and Policy at McGill University. Her research deals with the ethical, legal, and social implications surrounding access to data and genetic information, biobanking, and the regulation of stem cells, regenerative medicine, and new reproductive technologies. Erika is involved with the Stem Cell Network’s Trainee Communications and Training & Education Committees, as well as the coordinator of the pan-Canadian initiative aimed at assessing the adequacy of existing regulatory frameworks and considerations for reframing the Assisted Human Reproduction Act, in light of evolving reproductive technologies. She is also the Coordinator of the Canadian International Data Sharing Initiative (Can-SHARE) and the Access Officer of the Canadian Partnership for Tomorrow Project (CPTP). Erika’s interests expand to the potential implications of gene therapy / enhancement in minors within a sporting context.

Comités

Dr. Natasha Chang

Présidente du Comité de Programmes scientifiques
        
En savoir plus

Dr. Natasha Chang

Présidente du Comité de Programmes scientifiques

Dr. Natasha Chang received her Ph.D. in Biochemistry from McGill University, and pursued her postdoctoral fellowship at the Ottawa Hospital Research Institute. Dr. Chang joined McGill as an Assistant Professor in the Department of Biochemistry in 2019. Research in the Chang laboratory focuses on understanding the molecular signalling mechanisms that regulate muscle stem cell function and how these pathways are altered in the context of muscle degenerative disease and muscle cancer. The ultimate goal for Dr. Chang’s research team is to identify molecular targets to improve endogenous stem cell regenerative capacity as well as strategies to improve stem cell transplantation therapy.

Dr. Colin Crist

Président du Comité Web & communications
        
En savoir plus

Dr. Colin Crist

Président du Comité Web & communications

Dr. Crist’s laboratory at the Lady Davis Institute for Medical Research investigates the molecular biology underlying skeletal muscle development and regeneration. Deepening our understanding of how muscle stem cells develop and function will be key to realizing regenerative medicine based approaches to treating muscle disorders.

Prof. Terry Hébert

Président du Comité de Formation
        
En savoir plus

Prof. Terry Hébert

Président du Comité de Formation

Terry Hébert’s research focus is on the ontogeny, formation and trafficking of GPCR-based signalling complexes with a view toward understanding the architecture, wiring and integration of individual GPCR signalling pathways both at the cell surface and in the nucleus. Our primary focus is in the context of cardiovascular disease. He has developed new methods for in cellulo measures of protein/protein interactions and is highly involved in the development of new multiplexed signalling assays for drug discovery. The lab is now poised to exploit patient-derived iSPC lines to develop personalized understanding of disease and its treatment.

Me Erika Kleiderman

Présidente du Comité d'Éthique
        
En savoir plus

Me Erika Kleiderman

Présidente du Comité d'Éthique

Erika Kleiderman is a lawyer and an Academic Associate at the Centre of Genomics and Policy at McGill University. Her research deals with the ethical, legal, and social implications surrounding access to data and genetic information, biobanking, and the regulation of stem cells, regenerative medicine, and new reproductive technologies. Erika is involved with the Stem Cell Network’s Trainee Communications and Training & Education Committees, as well as the coordinator of the pan-Canadian initiative aimed at assessing the adequacy of existing regulatory frameworks and considerations for reframing the Assisted Human Reproduction Act, in light of evolving reproductive technologies. She is also the Coordinator of the Canadian International Data Sharing Initiative (Can-SHARE) and the Access Officer of the Canadian Partnership for Tomorrow Project (CPTP). Erika’s interests expand to the potential implications of gene therapy / enhancement in minors within a sporting context.

Dr. Vahab Soleimani

Président du Comité Prix & bourses
        
En savoir plus

Dr. Vahab Soleimani

Président du Comité Prix & bourses

My research program is focused on uncovering the epigenetic and transcriptional machinery that regulates stem cell self-renewal and differentiation using skeletal muscle regeneration as a model. Loss of stem cell or their diminished function underlies numerous muscle-wasting diseases. We are interested in identifying relevant molecular pathways that can be targeted by specific drugs to boost muscle stem cell self-renewal and expansion as a therapeutic strategy to treat muscle wasting-diseases.

Prof. Michel L. Tremblay

Président du Comité Financement & infrastructures
        
En savoir plus

Prof. Michel L. Tremblay

Président du Comité Financement & infrastructures

Dr. Michel L. Tremblay, Ph.D. is a James McGill Professor and former director of the Goodman Cancer Research Centre His laboratory works on characterizing the function and regulation of several members of the Protein Tyrosine Phosphatase (PTP) gene family using both biochemical and genetic approaches. Dr. Tremblay’s lab is also developing several new approaches towards PTP inhibition, as well as large siRNA gene family screens in order to uncover potential applications of these in various diseases (diabetes, obesity, spinal cord injury, neural degenerative diseases, intestinal bowel diseases and other inflammatory diseases), particularly in human cancers.

Copyright © 2019 Réseau de Médecine Régénérative de McGill. Tous droits réservés. Site Web par KORSR Studio, Valérie Provost & ER5.